Igenomix

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Igenomix sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).

4 total trials none currently recruiting 3 completed upper quartile by trial count

Igenomix: 4 sponsored US clinical trials, none currently recruiting.

Igenomix sponsors 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. The most-studied condition in this pipeline is Chromosome Abnormality, with 1 trials.

Upper-quartile sponsor footprint

Igenomix sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

4 total, page 1 of 1

COMPLETED

COVID-19: A Prevalence Study of Two ART Centres After the Pandemic Lockdown in the USA (COVID-19 Free Clinics)

NCT04466644
TERMINATED NA

Clinical Study of PGT-A Versus PGT-A+ERA

NCT03530254
COMPLETED

Multi-center Study to Validate niPGT-A

NCT03520933
COMPLETED

Development of a Microbiome Non-invasive Diagnosis Tool

NCT03330444

Therapeutic Areas

Chromosome Abnormality 1
Aneuploidy 1
Infertility 1

How the Igenomix archive is shaped

4 indexed studies, none listed as recruiting (0% open); 3 completed (75%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Chromosome Abnormality (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Igenomix: archived-pipeline peers nationwide

Peers matched on 4 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Igenomix sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60%80% Total trials Recruiting share Igenomix4D pharma60 Degrees PharmaceuticalsA2 BiotherapeuticsAbdul Latif Jameel Poverty Action Lab10xBio22nd Century Group23andMe3-C Institute for Social Development
Igenomix sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Igenomix sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 4 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Igenomix page

4 registered trials is a research-attention snapshot, not an endorsement of Igenomix or any single study.

  • None of Igenomix's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Chromosome Abnormality is the condition Igenomix studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Chromosome Abnormality trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Igenomix pipeline card: 4 registered trials from official public datasets.Report a data error.